Christos S Karapetis
Affiliation: Flinders University
- Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow upC S Karapetis
Department of Medical Oncology, Guy s Hospital, London, United Kingdom
Intern Med J 33:427-35. 2003..The objective of the present study was to evaluate the use of FDG-PET in the setting of advanced GCT, and to determine the influence of FDG-PET on subsequent patient management...
- PET and PLAP in suspected testicular cancer relapse: beware sarcoidosisC S Karapetis
Department of Medical Oncology, Guy's Hospital, London, UK
Ann Oncol 12:1485-8. 2001..Sarcoidosis, a condition that has been associated with testicular cancer, should always be considered in the differential diagnosis...
- K-ras mutations and benefit from cetuximab in advanced colorectal cancerChristos S Karapetis
Flinders Medical Centre and Flinders University, Adelaide, Australia
N Engl J Med 359:1757-65. 2008..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
- A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomasChristos S Karapetis
Department of Medical Oncology, Guy s Hospital, London, UK
Asia Pac J Clin Oncol 6:298-305. 2010..Epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) is a well-established chemotherapy regimen but a continuous chemotherapy infusion is not always feasible or acceptable...
- Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapySunita Padman
Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia
Acta Oncol 52:1699-706. 2013..Conversion chemotherapy has increased the population who are suitable for surgery. Here we assess patterns of care and treatment outcome in liver only metastases in South Australia using the clinical registry for advanced CRC...
- Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumorRajiv Kumar
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, Australia
Clin Colorectal Cancer 13:87-93. 2014..Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear...
- Current opinion on optimal treatment for colorectal cancerTimothy J Price
The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, South Australia, Australia
Expert Rev Anticancer Ther 13:597-611. 2013..This article reviews the evidence in support of modern treatments for CRC and the decision-making behind the treatment choices, their benefits and toxicities...
- A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal CancerRajiv Kumar
Department of Medical Oncology, Flinders Medical Center, Bedford Park, South Australia 5042, Australia
Cancer 119:722-8. 2013..Life expectancy is increasing, and more patients are presenting with cancer at an advanced age (≥80 years). Optimal management for this group of patients has not been well defined...
- Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factorsStephen J Clarke
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
Crit Rev Oncol Hematol 85:121-35. 2013..In this article, the current concepts of tumour and patient-related predictive factors in CRC management are reviewed...
- Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancerMuhammad A Khattak
Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia
Clin Colorectal Cancer 11:247-54. 2012..Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease...
- Cetuximab for the treatment of colorectal cancerDerek J Jonker
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
N Engl J Med 357:2040-8. 2007..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...